Immuneering Corporation (NASDAQ:IMRX) Receives $17.50 Consensus PT from Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $17.50.

Several research firms have weighed in on IMRX. Needham & Company LLC increased their price target on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Chardan Capital upgraded Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. UBS Group set a $14.00 target price on Immuneering in a report on Thursday, August 6th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMRX. PVG Asset Management Corp purchased a new position in Immuneering during the first quarter valued at approximately $773,000. Empery Asset Management LP bought a new position in shares of Immuneering in the fourth quarter worth approximately $17,601,000. Blue Owl Capital Holdings LP increased its stake in shares of Immuneering by 20.9% in the fourth quarter. Blue Owl Capital Holdings LP now owns 665,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 115,000 shares in the last quarter. 683 Capital Management LLC purchased a new stake in shares of Immuneering in the fourth quarter worth $992,000. Finally, DCF Advisers LLC bought a new stake in shares of Immuneering during the 4th quarter valued at $1,415,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Stock Up 0.2%

Shares of NASDAQ:IMRX opened at $4.45 on Monday. The firm’s 50 day moving average price is $4.76 and its 200-day moving average price is $4.97. Immuneering has a twelve month low of $3.86 and a twelve month high of $10.08. The stock has a market capitalization of $287.92 million, a PE ratio of -4.28 and a beta of 0.40.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). Analysts expect that Immuneering will post -1.09 earnings per share for the current fiscal year.

About Immuneering

Immuneering Corporation is a clinical-stage biotechnology company focused on developing medicines for cancer patients with limited treatment options. The company’s research centers on the mitogen-activated protein kinase (MAPK) pathway, a cellular signaling network frequently altered in solid tumors, including cancers driven by RAS mutations.

Immuneering’s lead product candidate is IMM-1-104, an oral therapy designed to provide deep and sustained inhibition of the MAPK pathway while using intermittent exposure to help normal cells recover.